Regional Sales 2002: A Company and Therapeutic Market Analysis

Introduction:

As the leading pharmaceutical companies increasingly face saturation in their home markets, geographical expansion will form a key part of their strategy going forward. Datamonitor assesses the global coverage of the top pharmaceutical companies and the breakdown of their sales in nine major therapy areas to assess the effective penetration of each brand in the major markets. 

Scope:

* Comparison of the regional sales breakdown of the top 18 pharmaceutical companies by total sales in 2001 

* Comparison of the regional sales breakdown of the top 15 drugs in 2001 

* Analysis of regional sales breakdown of nine major therapeutic markets, together with coverage of the major drugs 

Report Highlights:

The leading pharmaceutical companies are still focused on their market of origin, Merck & Co is the most US focused, with an estimated 83.4% of sales derived from the US. Accelerating geographic expansion will be the key driver of sales growth in the future, and will be accelerated through consolidation and exploitation of the alliance networks. 

The US market accounts for the majority of blockbuster drug sales, with 75.8% of the top 15 blockbusters sales derived from that market, compared to 49.9% of the market as a whole. 

Reasons to Purchase:

* Benchmark your geographic strategy against key rivals in the pharmaceutical sector 

* Evaluate the impact of geographic expansion on the potential sales of key drugs 

* Assess the regional variation of sales in key therapeutic markets 

Publisher: Datamonitor Market and Sales Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Market_and_Sales.html#a292